Abstract
Allogeneic islet transplantation is becoming a treatment option for patients with unstable type 1 diabetes melitus (T1DM). Around 80% of the islet recipients achieve insulin independence after one or two islet infusions under "Edmonton-like" immunosuppressive protocol, but only 10% will remain insulin independent over the long term. Islet transplantation leads to glucose stabilization, and severe hypoglycemia is prevented even in patients back on insulin injections. Thus, islet transplantation has achieved the proposed targets in patients with unstable T1DM: normalizing blood glucose and hemoglobin A1c, preventing severe hypoglycemic episodes, and improving quality of life. The current aims of islet transplantation programs are to maintain the success achieved and to overcome remaining obstacles and limitations.
| Original language | English |
|---|---|
| Pages (from-to) | 324-331 |
| Number of pages | 8 |
| Journal | Current Diabetes Reports |
| Volume | 8 |
| Issue number | 4 |
| DOIs | |
| State | Published - Aug 1 2008 |
Fingerprint
ASJC Scopus subject areas
- Endocrinology, Diabetes and Metabolism
- Internal Medicine
Cite this
Current challenges in islet transplantation. / Leitão, Cristiane B.; Cure, Pablo; Tharavanij, Thipaporn; Baidal, David; Alejandro, Rodolfo.
In: Current Diabetes Reports, Vol. 8, No. 4, 01.08.2008, p. 324-331.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Current challenges in islet transplantation
AU - Leitão, Cristiane B.
AU - Cure, Pablo
AU - Tharavanij, Thipaporn
AU - Baidal, David
AU - Alejandro, Rodolfo
PY - 2008/8/1
Y1 - 2008/8/1
N2 - Allogeneic islet transplantation is becoming a treatment option for patients with unstable type 1 diabetes melitus (T1DM). Around 80% of the islet recipients achieve insulin independence after one or two islet infusions under "Edmonton-like" immunosuppressive protocol, but only 10% will remain insulin independent over the long term. Islet transplantation leads to glucose stabilization, and severe hypoglycemia is prevented even in patients back on insulin injections. Thus, islet transplantation has achieved the proposed targets in patients with unstable T1DM: normalizing blood glucose and hemoglobin A1c, preventing severe hypoglycemic episodes, and improving quality of life. The current aims of islet transplantation programs are to maintain the success achieved and to overcome remaining obstacles and limitations.
AB - Allogeneic islet transplantation is becoming a treatment option for patients with unstable type 1 diabetes melitus (T1DM). Around 80% of the islet recipients achieve insulin independence after one or two islet infusions under "Edmonton-like" immunosuppressive protocol, but only 10% will remain insulin independent over the long term. Islet transplantation leads to glucose stabilization, and severe hypoglycemia is prevented even in patients back on insulin injections. Thus, islet transplantation has achieved the proposed targets in patients with unstable T1DM: normalizing blood glucose and hemoglobin A1c, preventing severe hypoglycemic episodes, and improving quality of life. The current aims of islet transplantation programs are to maintain the success achieved and to overcome remaining obstacles and limitations.
UR - http://www.scopus.com/inward/record.url?scp=52649127411&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=52649127411&partnerID=8YFLogxK
U2 - 10.1007/s11892-008-0057-3
DO - 10.1007/s11892-008-0057-3
M3 - Article
VL - 8
SP - 324
EP - 331
JO - Current Diabetes Reports
JF - Current Diabetes Reports
SN - 1534-4827
IS - 4
ER -